IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells

BACKGROUND: Recently, immunotherapy with anti-PD-1 antibodies has shown clinical benefit in recurrent Small Cell Lung Cancer (SCLC). Since anti-PD-1 re-activates anti-tumor Cytotoxic T Lymphocyte (CTL) responses, it is crucial to understand the mechanisms regulating HLA class I, and PD-L1 expression...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Exp Clin Cancer Res
Asıl Yazarlar: Carbotti, Grazia, Nikpoor, Amin Reza, Vacca, Paola, Gangemi, Rosaria, Giordano, Chiara, Campelli, Francesco, Ferrini, Silvano, Fabbi, Marina
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637329/
https://ncbi.nlm.nih.gov/pubmed/29020964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0608-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller